Suzetrigine Versus Usual-care Opioids for Postop Pain in Sports
Summary
The goal of this clinical trial is to learn if a Suzetrigine-based multimodal pain regimen can reduce the volume of opioid consumption while maintaining non-inferior pain control compared to an opioid-based multimodal pain regimen after common ambulatory orthopaedic sports procedures. The main questions it aims to answer are: 1. Does including Suzetrigine in the multimodal pain regimen lower the volume of opioids consumed by participants while maintaining non-inferior pain control? 2. How does the side-effect profile of a Suzetrigine-based multimodal postop pain regimen compare to that of an opioid-based multimodal postoperative pain regimen? Eligible participants will be assigned to receive one of the postop pain regimens and report their opioid use, their pain level, and the side effects they faced every day for 7 days.
Timeline
- Start
- 2026-02
- Primary completion
- 2026-07
- Completion
- 2026-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Suzetrigine | Small molecule | 50 mg | — |
| Background | Acetaminophen | Small molecule | 1000 mg | — |
| Background | Naproxen | Small molecule | 500 mg | — |
| Background | Oxycodone | Other / unclassified | 5 mg | — |
Indications
No indication recorded.